NEW YORK (GenomeWeb) – MDxHealth today said that it has signed a deal to buy NovioGendix, a firm developing a liquid biopsy test for prostate cancer, for $8.8 million. 

Based in Nijmegen, Netherlands, NovioGendix was spun out of Radboud University Medical Center in 2007 and provides diagnostic tests for prostate, bladder, kidney, and other urologic cancers. Its main focus is on developing a liquid biopsy test for prostate cancer that can identify patients at low risk for the disease. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.